Biosante Pharma News (AMEX:BPA)
| Latest Biosante Pharma News Headlines | | Date | Time | Source | | | 09/24/2007 | 1:57PM | PRNUS | WallSt.net Announces Upcoming Interview with CEO of BioSante Pharmaceuticals
NEW YORK, Sept. 24 /PRNewswire/ -- Stephen Simes, chief executive officer of BioSante Pharmaceuticals, Inc. (AMEX:BPA) (http://www.biosantepharma.com/) will be featured in an exclusive interview with http://www.wallst.net/ scheduled for September 26 at 10:30 a.m. EDT. The interview will be posted on http://www.wallst.net/... More...>> |
| 07/10/2007 | 7:00AM | PRNUS | WallSt.net (www.wallst.net ) Updates the Investment Community Through All-New Interviews with BPA, PPCO and NVAX
NEW YORK, July 10 /PRNewswire/ -- On June 19, Stephen Simes, CEO of Biosante Pharmaceuticals, Inc. (AMEX:BPA) (http://www.biosantepharma.com/ ) updated the investment community in an all-new interview with http://www.wallst.net/. Interview highlights include detailed discussions on the following topics:
-- the company's... More...>> |
| 06/13/2007 | 7:45AM | PRNUS | Bradley Pharmaceuticals Announces Launch of Elestrin(TM)
FAIRFIELD, N.J., June 13 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. (NYSE:BDY) today announced the launch of Elestrin(TM) (estradiol gel 0.06%) by the Company's Kenwood Therapeutics Division. Elestrin(TM) is an effective, low dose transdermal estrogen therapy that was approved by the Food and Drug Administration... More...>> |
| 05/04/2007 | 7:45AM | PRNUS | Bradley Pharmaceuticals to Preview New Products at ACOG Meeting
FAIRFIELD, N.J., May 4 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. (NYSE:BDY) today announced that it will preview two new FDA-approved products at the annual clinical meeting of the American College of Obstetricians and Gynecologists (ACOG) to be held in San Diego, California, from May 5-9, 2007. The Company's... More...>> |
| 04/11/2007 | 7:45AM | PRNUS | Bradley Pharmaceuticals' Elestrin(TM) Receives New Patent to 2022
FAIRFIELD, N.J., April 11 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. (NYSE:BDY) today announced that its partner, BioSante Pharmaceuticals (AMEX:BPA) was issued a new formulation patent for Elestrin(TM) (estradiol gel 0.06%). Elestrin(TM) was approved in December 2006 by the FDA for the treatment of moderate-to-severe... More...>> |
| 04/02/2007 | 1:09PM | PRNUS | Dawson James Securities Reiterates Strong Buy Recommendation on Antares Pharma (Amex: AIS) with $4.00 Price Target
BOCA RATON, Fla., April 2 /PRNewswire/ -- Dawson James Securities, a full- service investment firm serving the healthcare and biotechnology industry, reiterated their Strong Buy recommendation on Antares Pharma (AMEX:AIS) and a 12-18 month price target of $4.00. Stephen M. Dunn, Director of Research, issued the report.
The... More...>> |
| 12/19/2006 | 7:45AM | PRNUS | Bradley Pharmaceuticals Announces FDA Approval of Elestrin(TM) (estradiol gel 0.06%)
Elestrin(TM) to Be the Lowest Effective Dose of Estradiol Available
FAIRFIELD, N.J., Dec. 19 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. (NYSE:BDY) announced today that the Company has been notified by BioSante Pharmaceuticals (AMEX:BPA) that they received approval from the Food and Drug Administration to... More...>> |
| 11/08/2006 | 7:45AM | PRNUS | Bradley Pharmaceuticals Enters Into Agreement With BioSante Pharmaceuticals for Estradiol Transdermal Gel
FAIRFIELD, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. (NYSE:BDY) announced today that the Company has entered into an agreement with BioSante Pharmaceuticals (AMEX:BPA) to market BioSante's estradiol transdermal gel, Bio-E-Gel(R)* (estradiol), in the United States. The US Food and Drug Administration... More...>> |
| 06/07/2006 | 7:00AM | PRNUS | CCMH, IINT and BPA Update the Investment Community in All-New Interviews With www.wallst.net
NEW YORK, June 7 /PRNewswire/ -- On May 24, Dr. J. Greig, CEO of Chemical Consortium Holdings, Inc. (Pink Sheets: CCMH) updated the investment community in an all-new interview with http://www.wallst.net/. Interview highlights include detailed discussions on the following topics:
- current development projects... More...>> |
| 09/30/2005 | 7:00AM | PRNUS | Antares Pharma's Licensee Announces First Transdermal Estradiol Gel With Three Doses That Significantly Decrease Hot Flashes in
88% Decrease in Hot Flashes and the Lowest Effective Dose is Established, According to the Results Reported
EXTON, Pa., Sept. 30 /PRNewswire-FirstCall/ -- Antares Pharma, Inc. (AMEX:AIS) announced today that its North American licensee, BioSante Pharmaceuticals, Inc. (AMEX:BPA) has presented a full report of the results... More...>> |
| 01/19/2005 | 9:25AM | PRNUS | Antares Pharma's Licensee Reaches Important Milestone
Antares Pharma's Licensee Reaches Important Milestone
Antares Pharma's North American Licensee, BioSante Pharmaceuticals, Inc.,
Completes Enrollment in Pivotal Phase III Clinical Trial for Estradiol Gel
EXTON, Pa., Jan. 19 /PRNewswire-FirstCall/ -- Antares Pharma, Inc. (AMEX:AIS)
announced today that its North American... More...>> |
| 12/03/2004 | 9:39AM | PRNUS | BioSante Pharmaceuticals Comments on FDA Advisory Committee's Decision Not to Recommend Approval of Testosterone Patch
BioSante Pharmaceuticals Comments on FDA Advisory Committee's
Decision Not to Recommend Approval of Testosterone Patch
Investor Conference Call to be Held Today at 11 a.m. EST
LINCOLNSHIRE, Ill., Dec. 3 /PRNewswire-FirstCall/ -- BioSante Pharmaceuticals,
Inc. (AMEX:BPA) today offered comment on the decision not to recommend... More...>> |
| 11/04/2004 | 9:15AM | PRNUS | New Data Highlights Key Advantages of Antares Pharma's ATD(TM) Gel Technology When Compared to Transdermal Patches
New Data Highlights Key Advantages of Antares Pharma's ATD(TM)
Gel Technology When Compared to Transdermal Patches
EXTON, Pa., Nov. 4 /PRNewswire-FirstCall/ -- Antares Pharma, Inc. (AMEX:AIS),
a specialty pharmaceutical company that develops and licenses drug delivery
technology for the next generation lifestyle products... More...>> |
| 11/01/2004 | 7:00AM | PRNUS | First Transdermal Testosterone Gel to Significantly Increase Sexual Activity In Surgically Menopausal Women
First Transdermal Testosterone Gel to Significantly Increase
Sexual Activity In Surgically Menopausal Women
BioSante's LibiGel(TM) Shows 238% Increase in Frequency Of Satisfying Sexual
Events, According to Data at ISSWSH
LINCOLNSHIRE, Ill., Nov. 1 /PRNewswire-FirstCall/ -- BioSante Pharmaceuticals,
Inc. (AMEX:BPA) today... More...>> |
| 10/07/2004 | 3:44PM | PRNUS | Antares Pharma Announces Phase III Clinical Trial Update On Its Estradiol Advanced Transdermal Delivery (ATD(TM)) Gel By North A
Antares Pharma Announces Phase III Clinical Trial Update On Its
Estradiol Advanced Transdermal Delivery (ATD(TM)) Gel By North American
Licensee
EXTON, Pa., Oct. 7 /PRNewswire-FirstCall/ -- Antares Pharma, Inc. (AMEX:AIS),
an evolving specialty pharmaceutical company with headquarters in Exton,
Pennsylvania, today announced... More...>> |
| 09/22/2004 | 2:55PM | PRNUS | Antares Pharma's (OTCBB: ANTR / Amex: AIS as of September 23, 2004) North American Licensee BioSante Pharmaceuticals, Inc. Annou
Antares Pharma's (OTCBB: ANTR / Amex: AIS as of September 23,
2004) North American Licensee BioSante Pharmaceuticals, Inc. Announces Positive
Results of Phase II Study of LibiGel(TM), Topical Testosterone Gel
Antares Pharma Says Study Shows LibiGel(TM) Significantly Increases Sexual
Activity in Surgically Menopausal Women... More...>> |
| 09/15/2004 | 12:53PM | PRNUS | William Blair & Company Initiates Coverage of BioSante Pharmaceuticals, Inc. With Outperform Rating
William Blair & Company Initiates Coverage of BioSante
Pharmaceuticals, Inc. With Outperform Rating
CHICAGO, Sept. 15 /PRNewswire/ -- William Blair & Company today announced that
it initiated research coverage of BioSante Pharmaceuticals, Inc. (AMEX:BPA)
($7.85), a developmental-stage company building a portfolio of... More...>> |
| 07/23/2004 | 9:28AM | PRNUS | Webcast Alert: BioSante Pharmaceuticals, Inc. Presentation at Informed Investors Biotechnology/Healthcare Virtual Stocks Forum t
Webcast Alert: BioSante Pharmaceuticals, Inc. Presentation at
Informed Investors Biotechnology/Healthcare Virtual Stocks Forum to be Webcast
on Tuesday, July 27, 2004, 9:30 am ET
LINCOLNSHIRE, Ill., July 23 /PRNewswire/ -- BioSante Pharmaceuticals, Inc.
(AMEX:BPA) will present at the following forum:
What: BioSante... More...>> |
| 06/29/2004 | 10:30AM | PRNUS | Antares Pharma Partner Completes Phase II Clinical Trials for Testosterone Transdermal Gel in Female Sexual Dysfunction
Antares Pharma Partner Completes Phase II Clinical Trials for
Testosterone Transdermal Gel in Female Sexual Dysfunction
EXTON, Pa., June 29 /PRNewswire-FirstCall/ -- Antares Pharma Inc. (OTC:ANTR)
(BULLETIN BOARD: ANTR) said today that its U.S. licensee, BioSante
Pharmaceuticals, Inc. (AMEX:BPA) completed Phase II... More...>> |
| 06/18/2004 | 11:34AM | PRNUS | Forum Alert: BioSante Pharmaceuticals, Inc. Presentation at Informed Investors Biotechnology & Pharmaceuticals Stocks Forum at t
Forum Alert: BioSante Pharmaceuticals, Inc. Presentation at
Informed Investors Biotechnology & Pharmaceuticals Stocks Forum at the
Princeton Club in NYC on Wednesday, June 23, 2004, 1:30 pm ET
LINCOLNSHIRE, Ill., June 18 /PRNewswire/ -- Stephen Simes, President & Chief
Executive Officer of BioSante Pharmaceuticals... More...>> |
|
|
|